Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere AI-700 Imaging Agent Phase III Protocols Expected By Early 2002

Executive Summary

Acusphere plans to submit Phase III protocols for its ultrasound contrast agent AI-700 to FDA by early 2002.

You may also be interested in...



DuPont Pictures Definity Imaging Agent Launch Supported By User Training

DuPont Pharmaceuticals will support an autumn launch of its Definity echocardiography ultrasound contrast agent with a user training program.

Ivax Starts Shipping Generic Paclitaxel; Oral Formulation Paxoral In Phase II

Ivax has started shipping its generic version of Bristol's injectable anti-tumor agent Taxol (paclitaxel), Ivax President Neil Flanzraich told the CIBC World Markets Healthcare Conference in New York City Oct. 25.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel